• news.cision.com/
  • H. Lundbeck A/S/
  • H. Lundbeck, Lundbeck and Teva announce European submission of rasagiline as a treatment for Parkinson’s disease
Dansk

H. Lundbeck, Lundbeck and Teva announce European submission of rasagiline as a treatment for Parkinson’s disease

Report this content 

                        
H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. announced today that the rasagiline regulatory file has been submitted to the European Agency for Evaluation of Medicinal Products (EMEA) for the treatment of Parkinson’s disease (PD). This submission is based on data from three Phase III clinical trials which included over 1,500 PD patients, and follows the recent US and Canadian submissions.




                                            

                

            

        

    

    



    

        
 Abonner

        

            

        

    


        

            
        

        

            
        

        



    

        
 Dokumenter og links